argenx SE (NASDAQ:ARGX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of argenx SE (NASDAQ:ARGX) have earned an average recommendation of “Moderate Buy” from the twenty-two brokerages that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $658.39.

Several research analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft cut shares of argenx from a “hold” rating to a “sell” rating in a report on Friday, January 17th. Wedbush reiterated an “outperform” rating and set a $655.00 target price on shares of argenx in a report on Tuesday, December 3rd. Robert W. Baird lowered argenx from an “outperform” rating to a “neutral” rating and boosted their price target for the company from $515.00 to $650.00 in a report on Friday, November 1st. William Blair upgraded argenx from a “market perform” rating to an “outperform” rating in a report on Friday, November 1st. Finally, Evercore ISI boosted their target price on argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Stifel Financial Corp boosted its position in argenx by 15.3% during the third quarter. Stifel Financial Corp now owns 8,832 shares of the company’s stock worth $4,788,000 after purchasing an additional 1,170 shares during the period. FMR LLC boosted its holdings in shares of argenx by 35.9% during the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company’s stock worth $2,598,445,000 after buying an additional 1,265,486 shares during the period. Simplify Asset Management Inc. grew its stake in argenx by 64.0% in the 3rd quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company’s stock valued at $1,311,000 after buying an additional 944 shares during the last quarter. Perpetual Ltd bought a new position in argenx in the 3rd quarter valued at about $76,314,000. Finally, Logos Global Management LP acquired a new stake in argenx during the second quarter worth approximately $58,055,000. 60.32% of the stock is owned by institutional investors and hedge funds.

argenx Trading Up 1.1 %

ARGX stock opened at $647.39 on Friday. argenx has a 1-year low of $349.86 and a 1-year high of $678.21. The firm has a market cap of $39.08 billion, a PE ratio of -735.67 and a beta of 0.59. The business’s 50-day moving average price is $622.29 and its two-hundred day moving average price is $560.29.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $588.88 million for the quarter, compared to analysts’ expectations of $543.29 million. During the same quarter in the previous year, the business posted ($1.25) EPS. On average, analysts forecast that argenx will post 2.51 earnings per share for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.